BioSpace News Archive

Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.

CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.

vTv Therapeutics Inc. today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments.

Today Freenome, a privately held biotech company, presents a subject population analysis from PREEMPT CRC, a study for the detection of colorectal cancer (CRC) at the Western Colorectal Cancer Consortium Conference in Portland, Oregon.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1).

Incyte announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology Annual Meeting, held March 17-21, 2023, in New Orleans.

OnPoint, a group of privately held augmented reality (AR) technology companies pioneering AR guidance for multiple spine, neurosurgical, and orthopedic, including robotic, procedures, today announced that it will participate in the 2023 Canaccord Genuity Musculoskeletal Conference, which will take place on March 7th, 2023.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET.

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will provide a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14 at 10:40 a.m. ET.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the fourth quarter and full year ending December 31, 2022.